NeurologyLive® Friday 5 — November 14, 2025

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: FDA Action Update, October 2025: Clearance, Acceptance, and Extension

Catch up on any of the neurology news headlines you may have missed in October 2025, compiled into 1 place by the NeurologyLive team.

2: Next Phase of Genetic Counseling in Clinical Trials: Derek Ansel, MS, CGC

The vice president of Rare Disease Strategy at Worldwide Clinical Trials discussed how genetic counselors are becoming integral to the design, execution, and interpretation of clinical research. [WATCH TIME: 3 minutes]

3: Reflecting on the 2025 Annual Women in Neurology (WNG) Conference: Amy Hessler, DO

The co-founder of the Women Neurologists Group shared her experiences from the 4th Annual Women in Neurology Conference in Colorado Springs, highlighting its focus on education and wellness. [WATCH TIME: 6 minutes]

4: NeuroVoices: Fabian Somers, PhD, on the First Approved Drug for Thymidine Kinase 2 Deficiency

The vice president and Asset Head of Rare and Ultra-Rare Diseases at UCB provided clinical perspectives on the FDA approval of Kygevvi, the first marketed treatment specific for patients with thymidine kinase 2 deficiency (Tk2d).

5: Uniting Organizations to Collectively Advocate for Neuromuscular Diseases: Paul Melmeyer, MPP

The executive vice president of public policy and advocacy at the Muscular Dystrophy Association discussed how collaboration can improve policy, funding, and care for patients with neuromuscular diseases. [WATCH TIME: 7 minutes]